“The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering new hope to patients suffering from C...
The tender offer, which was previously scheduled to expire at one minute past 11:59 p.m., Eastern time, on Nov. 9, 2023, has been extended until 5:00 p.m.,...
Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% S...
Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of mu...
Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organ...
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition ...
“The new share buyback authorization is consistent with our disciplined approach and demonstrates our continued commitment to using this tool as part...
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make ...
Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 Aug...
Under CEO Alan Hirzel’s leadership, Abcam has transformed as a business, created significant value for all stakeholders, and outperformed the m...
Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 Aug...
QIAGEN N.V. announced a notice (reiterating its notice to holders dated January 9, 2019) to holders of the following: - 0.500% Senior Unsecure...
Bristol Myers Squibb (NYSE: BMY) announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on th...
The repurchases will be executed through one or more individual forward transactions, expected to be entered into in the second and/or the third quarter of...
© 2024 Biopharma Boardroom. All Rights Reserved.
